A Trial of Firesorb in Patients With Coronary Artery Disease: FUTURE-II

A trial with no phase registered on ClinicalTrials.gov. The registry status is completed. It enrolled 430 participants.

Also called NCT02890160

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; single masking; primary purpose treatment
Phase
Not applicable
Enrolled
  • 430 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT02890160
Other papers using this trial's data
  • Thinner Strut Sirolimus-Eluting BRS Versus EES in Patients With Coronary Artery Disease: FUTURE-II Trial JACC. Cardiovascular interventions, 2021-07-12 DOI, PubMed 34238555

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
China (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02890160. Randomized; single masking; primary purpose treatment. Start 2017-08-24 (actual); primary completion 2020-10-31 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Trial of Firesorb in Patients With Coronary Artery Disease: FUTURE-II
Acronym
FUTURE-II
Intervention (Device)
Firesorb
Intervention (Device)
XIENCE
Lead sponsor
Shanghai MicroPort Medical (Group) Co., Ltd. (class: industry)

Record details

Record id
cardio:ct-nct02890160
Content hash
bf7179f0c8a6403ed7d5de936576427e81ec588707f2b5ff806d967ea6abf640